New aspects in the treatment of asthma: targeted therapy.
Wang
Zeng-li
ZL
Department of Respiratory Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China wangzengli@tom.com
D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology; D016207:Cytokines / Q000037:antagonists & inhibitors; D006801:Humans; D015848:Interleukin-5 / Q000037:antagonists & inhibitors; D000069444:Omalizumab; D019948:Receptors, Interleukin-4 / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000502:physiology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D016207:Cytokines; D015848:Interleukin-5; D019948:Receptors, Interleukin-4; D014409:Tumor Necrosis Factor-alpha; C026408:anti-IgE antibodies; D000069444:Omalizumab